PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical and translational medicine - 12(2022), 4 vom: 21. Apr., Seite e806 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Acharya, Arpan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 11.04.2022 Date Revised 05.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/ctm2.806 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339199369 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339199369 | ||
| 003 | DE-627 | ||
| 005 | 20240108142020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ctm2.806 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM339199369 | ||
| 035 | |a (NLM)35390226 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Acharya, Arpan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2022 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a BRD4 protein, human |2 NLM | |
| 650 | 7 | |a Cell Cycle Proteins |2 NLM | |
| 650 | 7 | |a Phosphoinositide-3 Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a MTOR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Pathania, Anup S |e verfasserin |4 aut | |
| 700 | 1 | |a Pandey, Kabita |e verfasserin |4 aut | |
| 700 | 1 | |a Thurman, Michellie |e verfasserin |4 aut | |
| 700 | 1 | |a Vann, Kendra R |e verfasserin |4 aut | |
| 700 | 1 | |a Kutateladze, Tatiana G |e verfasserin |4 aut | |
| 700 | 1 | |a Challagundala, Kishore B |e verfasserin |4 aut | |
| 700 | 1 | |a Durden, Donald L |e verfasserin |4 aut | |
| 700 | 1 | |a Byrareddy, Siddappa N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational medicine |d 2012 |g 12(2022), 4 vom: 21. Apr., Seite e806 |w (DE-627)NLM224642685 |x 2001-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:4 |g day:21 |g month:04 |g pages:e806 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ctm2.806 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 4 |b 21 |c 04 |h e806 | ||